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ABSTRACT
Background Precision medicine involves three major innovations currently tak-
ing place in healthcare: electronic health records, genomics and big data. A major 
challenge for healthcare providers is, however, understanding the readiness for the 
practical application of initiatives like precision medicine.
Objective To better understand the current state and challenges of precision 
medicine interoperability using a national genetic testing registry (GTR) as a start-
ing point, placed in the context of established interoperability formats.
Methods We performed an exploratory analysis of the National Institutes of 
Health GTR. Relevant standards included Health Level Seven International Version 
3 Implementation Guide for Family History, the Human Genome Organization Gene 
Nomenclature Committee (HGNC) database and Systematised Nomenclature of 
Medicine – Clinical Terms (SNOMED CT). We analysed the distribution of genetic 
testing laboratories, genetic test characteristics and standardised genome/clinical 
code mappings, stratified by laboratory setting.
Results There were a total of 25,472 genetic tests from 240 laboratories testing 
for approximately 3,632 distinct genes. Most tests focused on diagnosis, muta-
tion confirmation and/or the risk assessment of germline mutations that could be 
passed to offspring. Genes were successfully mapped to all HGNC identifiers, but 
less than half of tests were mapped to SNOMED CT codes, highlighting significant 
gaps when linking genetic tests to standardised clinical codes that explain the medi-
cal motivations behind test ordering.
Conclusion While precision medicine could potentially transform healthcare, 
successful practical and clinical applications will first require the comprehensive 
and responsible adoption of interoperable standards, terminologies and formats 
across all aspects of the precision medicine pipeline.
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INTRODUCTION
Over the last few years, healthcare has been undergoing dra-
matic transformation due to the rapid growth of three important 
innovations: electronic health records (EHRs), genomics and 
big data. The Affordable Care Act has substantially increased 
the volume of patients demanding care and is transforming 
the way healthcare organisations must provide that care. In 
particular, healthcare providers will be held more accountable 
for their ability to meet important quality measures such as 
adequate control of chronic disease, broad preventive health-
care and significant reductions in hospitalisations.1 Similarly, 
the Health Information Technology for Economic and Clinical 
Health Act has led to a dramatic increase in the adoption of 
EHR technology throughout the country.2 The development 
of mandated meaningful use requirements and interoper-
ability standards has propelled the growth and availability 
of EHRs and other forms of health information technology 
(IT).1 This influx of new regulations and digital records will 
encourage large amounts of clinical and quality data to be 
managed, shared and applied across diverse organisations 
and institutions.3
At the same time that EHRs are providing increased 
access to clinical information, the sequencing of the human 
genome over a decade ago has catalysed new discoveries 
explaining the genetic contributions of a patient’s susceptibil-
ity to disease.4 Precision medicine is broadly defined as the 
application of patient-specific health and genomic information 
for highly targeted and effective methods of clinical diagno-
sis, management and treatment.5,6 This genomic data can 
come from many sources, from single and multigene tests to 
the sequencing of exomes and entire genomes, all of which 
provide valuable insight into the human clinical condition.4 
Precision medicine has the potential to leverage health IT in 
ways that could dramatically improve public and population 
health, bringing practical genomic information exchange into 
sharp focus.7
A major challenge for healthcare providers is, however, the 
rapid and dramatic increase in the volume and complexity of 
data that must now be collected, organised and evaluated.2 
For EHRs, the large amount of clinical information includes 
medical history, laboratory results, imaging files and other 
data collected during the patient appointment.2 For genomics, 
this involves descriptive metadata along with the sequenced 
genome of a patient, which (at roughly six billion base pairs in 
size) will require significant investments in storage, analysis 
and dynamic interpretation.4 These challenges will be com-
pounded exponentially when scaled to the patient population 
affected by EHR adoption and genomics. It is widely pre-
dicted that current EHRs alone will not be capable of handling 
the volume and complexity of genomic information central to 
the practice of precision medicine.8–10 Indeed, no universally 
accepted approach exists for describing clinically relevant 
genomic findings, and a very few EHRs today even attempt to 
report both clinical and genomic data at the point of care.11–13 
As a result, understanding the current state of precision med-
icine interoperability will be a key first step towards effectively 
annotating results and communicating genetic test informa-
tion across different health IT systems.14,15 The goal of this 
study is to analyse the genetic testing registry (GTR) in the 
context of relevant health IT nomenclatures and standards in 
order to understand the practical challenges in addressing 
interoperability for precision medicine.
METHODS
Data collection, definition and classification
The National Institutes of Health (NIH) GTR provides a com-
prehensive description of registered genetic tests being 
offered by various laboratories and organisations for clinical 
applications.16 Laboratories add their genetic tests to the reg-
istry by submitting an online template with detailed informa-
tion about their test and its applications. Minimum required 
fields include the genetic test name, purpose, laboratory infor-
mation, methodology and related conditions/phenotypes.16,17 
The test purpose required field, described in detail online, cur-
rently includes twelve indications for a genetic test (for which 
multiple selections are allowed): diagnosis, drug response, 
monitoring, mutation confirmation, pre-implantation genetic 
diagnosis, pre-symptomatic assessment of high-penetrance 
genetic disorders, risk assessment, screening, prognostic, 
predictive, recurrence and therapeutic management.16,17 A 
full version of the GTR data set was downloaded from the 
NIH GTR website.17 In particular, this included the complete 
public data set and additional files describing genetic tests, 
disease names, and gene-disease relationships. 
Using available organisations, institutions and/or depart-
ment names, laboratories that offered or performed genetic 
testing were classified into four categories according to the 
specific organisational setting in which genetic testing was 
performed: 1) Academic/Hospital (laboratories affiliated with 
a university or medical center), 2) Company (laboratories part 
of for-profit organisations or companies), 3) Institute/Center 
(laboratories affiliated with a non-academic/non-medical 
institute or center), and 4) Other (laboratories not falling into 
any prior category).
Interoperability standards and databases
As a starting point for assessing health IT conformance to 
standards for exchanging genomic data, we chose the Health 
Level Seven International (HL7) Version 3 Implementation 
Guide for Family History/Pedigree Interoperability, Release 
1.18 In particular, the minimal core data set in this standard 
requires mapping data to the Human Genome Organisation 
Gene Nomenclature Committee (HGNC) database that 
includes National Center for Biotechnology Information 
(NCBI) RefSeq identifiers. Clinical conditions targeted by 
various genetic tests were further described in the registry 
as Systematised Nomenclature of Medicine – Clinical Terms 
(SNOMED CT) codes.
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Analytics pipeline and statistical analysis
Using the above definitions, categories and interoperability 
standards, an analytical pipeline was created in the Python 
programming language to extract all clinical genetic test 
information from the NIH GTR, to map available genetic test 
data to standard identifiers in the HGNC database, and to 
create an integrated data set for analysis.19 Summary sta-
tistics were collected for categorical data as frequencies and 
percentages, with differences (laboratory setting according 
to mutation type, the number of genes tested, test purpose 
and SNOMED CT mapping status, respectively) evaluated 
using chi-square or Fisher’s exact test, as appropriate. A P 
value <0.05 was considered significant. Analyses were per-
formed using R version 3.1.1 (R Foundation for Statistical 
Computing) and open source statistical software PSPP ver-
sion 0.8.4.
RESULTS
Genetic testing registry characteristics
There were a total of 25,472 genetic tests from 240 differ-
ent laboratories in the NIH GTR, testing for approximately 
3,632 distinct genes. Of these tests, 23,999 (94.2%) were 
submitted directly to the NIH GTR, while 1,473 (6.1%) car-
ried over from the prior GeneTests Laboratory Directory. The 
distribution of laboratory categories included 125 (52.1%) 
laboratories in the Academic/Hospital setting, 65 (27.1%) 
affiliated with a Company, 28 (11.7%) from an Institute/
Center and 22 (9.2%) in Other. Multiple genes were evalu-
ated in 1,933 (8.1%) tests, often as part of panels that may 
use next-generation sequencing methods, while most of the 
remaining 22,066 (92.0%) genetic tests submitted directly to 
the registry focused on evaluating or assessing single genes 
(Table 1). Further, 23,829 (99.3%) tests focused on germline 
mutations, 113 (0.5%) on somatic mutations and 57 (0.2%) 
did not provide this information (Table 1). On average, there 
were 50.5 tests per Academic/Hospital site, 206.7 tests per 
Company site, 94.1 tests per Institute/Center site and 73.5 
tests per Other site.
Purpose of genetic testing
The reported purposes for each genetic test were as follows: 
23,274 (97.0%) diagnosis, 147 (0.6%) drug response, 384 
(1.6%) monitoring, 11,119 (46.3%) mutation confirmation, 
151 (0.6%) pre-implantation diagnosis, 5,354 (22.3%) pre-
symptomatic, 609 (2.5%) predictive, 146 (0.6%) prognostic, 
29 (0.1%) recurrence, 5,668 (23.6%) risk assessment, 4,741 
(19.8%) screening and 154 (0.6%) therapeutic management. 
By laboratory setting (Table 2), the top three reported pur-
poses by test volume were diagnosis (6,122), mutation con-
firmation (4,418) and risk assessment (3,343) for Academic/
Hospital; diagnosis (13,055), mutation confirmation (5,260) 
and pre-symptomatic (2,083) for Company; diagnosis (2,631), 
mutation confirmation (855) and risk assessment (528) for 
Institute/Center; and diagnosis (1,466), mutation confirma-
tion (586) and pre-symptomatic (345) for Other.
Interoperability mappings related to 
precision medicine
All 3,632 genes could be matched to an approved gene sym-
bol from HGNC, and 3,594 (99.0%) of these genes were suc-
cessfully mapped to NCBI RefSeq identifiers. There were 
a total of 5,318 conditions associated with these tests, with 
1,163 (21.9%) conditions in the registry currently assigned a 
SNOMED CT code. Out of 1,160 SNOMED CT codes, 146 
(12.6%) mapped to a single genetic test, while 1,014 (87.4%) 
mapped to multiple genetic tests. Alternatively, the extent 
that genetic tests in the NIH GTR could be mapped to one or 
more SNOMED CT codes, as shown in Table 3. Furthermore, 
tests in both the Institute/Center and Other laboratory set-
tings mapped to as many as ten different SNOMED CT 















 Germline 6282 (99.5) 13315 (99.1) 2625 (99.7) 1607 (99.4)
 Somatic 28 (0.4) 68 (0.5) 8 (0.3) 9 (0.6)
 Unknown 2 (0.0) 54 (0.4) 1 (0.0) 0 (0.0)
Genes tested, 
No (%)b
 Single gene 5772 (91.4) 12431 (92.5) 2503 (95.0) 1360 (84.2)
 Multiple genes 540 (8.6) 1006 (7.5) 131 (5.0) 256 (15.8)
Table 1 Genetic test characteristics by laboratory setting
ap < 0.001 comparing distribution of mutation types by Laboratory setting
bp < 0.001 comparing distribution of genes number by Laboratory setting














Diagnosis 6122 (97.0) 13055 (97.2) 2631 (99.9) 1466 (90.7)
Drug Response 63 (1.0) 61 (0.5) 11 (0.4) 12 (0.7)
Monitoring 360 (5.7) 18 (0.1) 5 (0.2) 1 (0.1)
Mutation 
Confirmation
4418 (70.0) 5260 (39.1) 855 (32.5) 586 (36.3)
Pre-implantation 
diagnosis
103 (1.6) 7 (0.1) 23 (0.9) 18 (1.1)
Pre-symptomatic 2828 (44.8) 2083 (15.5) 98 (3.7) 345 (21.3)
Predictive 29 (0.5) 530 (3.9) 10 (0.4) 40 (2.5)
Prognostic 93 (1.5) 37 (0.3) 12 (0.5) 4 (0.2)
Recurrence 5 (0.1) 5 (0.0) 1 (0.0) 18 (1.1)
Risk Assessment 3343 (53.0) 1637 (12.2) 528 (20.0) 160 (9.9)
Screening 2138 (33.9) 2010 (15.0) 415 (15.8) 178 (11.0)
Therapeutic 
Management
18 (0.3) 126 (0.9) 8 (0.3) 2 (0.1)
aPercentages do not sum to 100 since multiple purposes can be reported for tests
bp < 0.001 comparing distribution of test purpose by laboratory setting
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(e.g. Baylor MitoMet Plus aCGH analysis) and Company (e.g. 
Illumina TruGenome Predisposition Screen) settings mapped 
to over 250 and 500 SNOMED CT codes, respectively.
DISCUSSION
Precision medicine is expected to play a key role in trans-
forming healthcare, and interoperable health IT provides the 
critical infrastructure around which precision medicine can 
be applied. To the author’s knowledge, this is the first study 
to assess the current state of precision medicine interoper-
ability by analyzing GTR data with existing interoperability 
standards. This study is timely given the announced U.S. 
Precision Medicine Initiative (PMI), also known as the NIH 
All of Us Research Program, and the rapid convergence of 
health IT, genomics and big data analytics.7,20,21
There were a large number of registered genetic tests for a 
diverse set of genes focused primarily on diagnosis, mutation 
confirmation and/or risk assessment. When broken down by 
laboratory setting, academic institutions focused primarily on 
the diagnosis or confirmation of mutations, while companies 
reported a much more diverse set of registered purposes. 
This likely reflects the differing priorities and varied stake-
holders involved for these settings. Companies, for exam-
ple, develop tests for a broad set of stakeholders (including 
directly to consumers) consistent with the diverse reported 
test purposes, while tests at academic hospitals focus heav-
ily on helping physicians, addressing the clinical diagnostic 
needs of their patient populations.22
While tests for germline mutations that could be passed 
to offspring predominated, the expansion of registry submis-
sion criteria will likely lead to a growing volume of genetic 
tests for somatic mutations as well.16 The relatively small 
volume of tested genes in the registry likely reflects the cur-
rent lack of evidence supporting the clinical validity and util-
ity of most genes in the human genome; furthermore, unlike 
analytical validity, clinical validity and utility remain optional 
entries in the NIH GTR.2,16 Even at this early stage of pre-
cision medicine, however, several laboratories have begun 
offering genomic sequencing services and evaluating large 
panels of genes.17 Oncology is an example of one important 
area for precision medicine, and where an understanding of 
the human genome has guided not only disease risk assess-
ment and diagnosis, but also selection of the most effective 
treatments for patients as well.7,23,24 As new guidelines and 
standards for identifying, classifying and assessing evidence 
for genomic data are developed, the breadth of clinically rel-
evant genes will likely expand considerably over time.25,26
The successful application of precision medicine in prac-
tice will require health IT capable of processing large vol-
umes of genomic data and presenting relevant results to 
physicians at the point of care.2,4,27 While the largest number 
of laboratories came from the Academic/Hospital setting, the 
largest volume of actual tests originated from companies; in 
particular, there were twice as many academic/hospital labs 
than company laboratories, yet those companies registered 
twice as many genetic tests. Prior studies have shown dif-
ferent types of physicians order different genetic tests, and 
this study similarly showed that different organisations focus 
on different types of assays.22 Effective practical adoption of 
precision medicine will require a strong understanding of the 
diverse backgrounds and behaviours of stakeholders, rang-
ing from patients being tested to providers ordering tests to 
the labs building new technologies.22,28
One major purpose of the NIH GTR is to help healthcare 
providers to make informed decisions about the need to order 
genetic tests for patients.16 Genomic clinical decision support 
largely depends on the ability to connect genetic informa-
tion with relevant clinical conditions at the point of care.27,28 
While the majority of genes were successfully mapped to 
both HGNC-approved gene symbols and NCBI RefSeq iden-
tifiers, a majority of genetic tests did not have any SNOMED 
CT code assigned to them, reflecting a critical gap in core 
information needed for the practice of precision medicine. 
The voluntary nature of the GTR is likely a major contribu-
tor to the poor degree of clinical mapping. In particular, not 
only is submission to the NIH GTR optional for organisations, 
but critical data fields (e.g. clinical codes, clinical validity 
and clinical utility) are currently the optional components of 
each submission as well. A required mapping of medical and 
clinical terms through a mandatory registry submission pro-
cess would make the NIH GTR a more valuable resource to 
help physicians make sense of the overwhelming volume of 
genomic information that may soon be integrated into clinical 
care.2,4,27,29
Currently, multiple genetic tests map to a single SNOMED 
CT code, obligating physicians to spend time deciding among 
multiple options for the same clinical indication. The presence 
Table 3 Mapping of tests to clinical codes by laboratory setting













Single code 2419 (38.3) 4550 (33.9) 1082 (41.1) 603 (37.3) 8654 (36.1)
Multiple codes 558 (8.8) 766 (5.7) 102 (3.9) 132 (8.2) 1558 (6.5)
Single/multiple codes 2977 (47.2) 5316 (39.6) 1184 (45.0) 735 (45.5) 10212 (42.6)
Unmapped 3335 (52.8) 8121 (60.4) 1450 (55.0) 881 (54.5) 13787 (57.4)
ap < 0.001 comparing mapping status by laboratory setting
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of incomplete or confusing clinical mappings for genetic tests 
is likely due to current uncertainty around which standards 
should be used to map genetic data with other types of medical 
information.29–31 The U.S. Federal Government’s Precision 
Medicine Task Force, for example, is responsible for recom-
mending the set of standards to be used for exchanging data 
for the million (or more) patients expected to participate in the 
National PMI. Yet even with hundreds of relevant standards 
available, from Fast Healthcare Interoperability Resources 
to HL7 Clinical Genomics standards to the Global Alliance 
for Genomic Health, surprisingly only one standard (HL7’s 
Family Health History/Pedigree) has been recognised by the 
task force as mature enough for practical use in the PMI.32,33 
Strong multidisciplinary leadership capable of addressing the 
critical technical, regulatory and interoperability gaps will be 
needed so that the vision of precision medicine can become 
a practical reality.
Our study had several limitations. First, the results may 
not be generalisable since the GTR is a voluntary registry 
that may not capture every laboratory offering genetic testing 
services, and selection bias is thus possible. However, this 
NIH-based registry currently represents the most compre-
hensive attempt at creating a centralised resource of genetic 
tests and laboratories for the healthcare community, and will 
likely become more complete over time with the growing 
focus on precision medicine.16 Second, the dynamic nature 
of genomic medicine means that any categories used in our 
study to describe genetic tests will likely change as the field 
evolves. However, our study provides a solid starting point for 
gaining useful insight into the current state of precision medi-
cine, and language describing the field will begin to stabilise 
as standards are adopted, guidelines are developed and poli-
cies and regulations are put in place.7,31,34–36 Finally, there 
is a wealth of available standards and formats that could be 
applied to precision medicine, but the analysis of any single 
standard would not be able to adequately address every 
major issue. The primary purpose of our study was to take a 
data-driven approach to assessing the challenges and oppor-
tunities of precision medicine through the lens of health IT 
interoperability. As precision medicine evolves from assess-
ing genetic tests to applying sequenced genomes, informat-
ics approaches can be used to provide valuable insight into 
the wealth of diverse data describing all aspects of health-
care IT.27
In conclusion, the practice of precision medicine enabled 
by interoperable health IT has the potential to dramatically 
improve healthcare. However, this will first require the com-
prehensive but responsible adoption and implementation of 
appropriate standards, terminologies and formats across all 
aspects of the precision medicine pipeline. 
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